Jefferies Group Comments on Diasorin Spa’s FY2017 Earnings (DSRLF)
Diasorin Spa (OTCMKTS:DSRLF) – Equities researchers at Jefferies Group issued their FY2017 earnings estimates for Diasorin in a research note issued to investors on Monday. Jefferies Group analyst P. Welford anticipates that the company will earn $3.53 per share for the year. Jefferies Group also issued estimates for Diasorin’s Q4 2017 earnings at $1.22 EPS, FY2018 earnings at $3.62 EPS, FY2019 earnings at $3.84 EPS, FY2020 earnings at $4.05 EPS and FY2021 earnings at $4.26 EPS.
Separately, Zacks Investment Research downgraded shares of Diasorin from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 5th.
WARNING: “Jefferies Group Comments on Diasorin Spa’s FY2017 Earnings (DSRLF)” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://theolympiareport.com/2018/02/15/jefferies-group-comments-on-diasorin-spas-fy2017-earnings-dsrlf.html.
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages.
Receive News & Ratings for Diasorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diasorin and related companies with MarketBeat.com's FREE daily email newsletter.